New personalised cancer vaccine has cut the risk of skin cancer spreading by 42% in a clinical trial. The new drug combination reduces melanoma risk by 38% over two years. Personalised medicine is already being tested against other cancers, including kidney and bladder cancer.
Two years after starting the jab, patients were far less likely to have melanoma. Experts say it's a "fantastic technology" for patients enrolled in the trial. Three years on, he is having checks every six months.
Both companies say they are "engaging with authorities" a personalised vaccine will be made for each individual patient. The trial will continue so that patients involved can be monitored.
This summary was written with AI assistance from the original article and may leave out important context. The original reporting belongs to BBC News · Health. Check the original, and official sources, before acting on any detail.